Byetta - First-in-Class Incretin Mimetic for Type 2 Diabetes, No Country
Key Data:
Drug (brand/generic)
Exenatide (AC2993)
Company/licensee
Amylin Pharmaceuticals/ Eli Lilly
Therapy class
Incretin mimetics
Product description
Synthetic exendin-4 agent with structural similarities to GLP-1
Current indication
Type 2 diabetic patients poorly controlled with diet plus metformin and/or sulfonylureas.
Market sector
Diabetes
Development status
Pre-registration US
